Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E44.00 EPS (ttm)0.60 Insider Own0.53% Shs Outstand435.07M Perf Week-8.52%
Market Cap11.51B Forward P/E12.58 EPS next Y2.10 Insider Trans0.00% Shs Float433.23M Perf Month-5.74%
Income262.28M PEG- EPS next Q- Inst Own6.81% Short Float0.47% Perf Quarter1.93%
Sales5.53B P/S2.08 EPS this Y8.81% Inst Trans8.89% Short Ratio2.11 Perf Half Y-2.97%
Book/sh12.03 P/B2.20 EPS next Y16.56% ROA2.63% Short Interest2.02M Perf Year-7.91%
Cash/sh0.69 P/C38.10 EPS next 5Y-8.00% ROE5.01% 52W Range21.52 - 33.08 Perf YTD-3.15%
Dividend Est.0.80 (3.02%) P/FCF64.09 EPS past 5Y-16.84% ROI3.48% 52W High-20.15% Beta0.73
Dividend TTM0.75 (2.84%) Quick Ratio0.72 Sales past 5Y2.86% Gross Margin68.83% 52W Low22.74% ATR (14)0.53
Dividend Ex-DateOct 05, 2023 Current Ratio1.77 EPS Y/Y TTM16.97% Oper. Margin8.39% RSI (14)34.58 Volatility2.06% 1.52%
Employees20122 Debt/Eq0.59 Sales Y/Y TTM3.44% Profit Margin4.75% Recom1.89 Target Price32.37
Option/ShortYes / Yes LT Debt/Eq0.44 EPS Q/Q84.85% Payout142.72% Rel Volume0.99 Prev Close26.51
Sales Surprise0.46% EPS Surprise-1.03% Sales Q/Q1.81% EarningsFeb 27 BMO Avg Volume955.84K Price26.42
SMA20-5.65% SMA50-4.37% SMA200-3.80% Trades Volume945,589 Change-0.34%
Date Action Analyst Rating Change Price Target Change
Nov-28-23Upgrade Barclays Underweight → Equal Weight
Nov-03-23Upgrade JP Morgan Neutral → Overweight
Oct-31-23Upgrade HSBC Securities Hold → Buy
Oct-13-23Initiated Stifel Hold
Aug-08-23Upgrade UBS Sell → Neutral
Apr-27-23Downgrade HSBC Securities Buy → Hold
Apr-11-23Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-12-22Initiated Citigroup Buy
Nov-28-22Downgrade UBS Neutral → Sell
Oct-18-22Initiated Morgan Stanley Equal-Weight
Feb-28-24 12:52PM
Feb-27-24 05:09PM
04:19PM Loading…
Feb-21-24 09:40AM
Feb-13-24 08:00AM
Feb-12-24 03:00PM
Feb-10-24 12:03PM
Jan-24-24 09:40AM
Jan-18-24 08:38PM
Jan-14-24 04:00PM
07:00AM Loading…
Jan-11-24 07:00AM
Nov-28-23 11:31AM
Nov-27-23 01:33AM
Nov-03-23 06:25PM
Oct-11-23 02:00AM
Oct-05-23 07:06AM
Oct-03-23 05:02AM
Oct-02-23 09:15AM
Sep-29-23 09:40AM
Sep-21-23 08:24PM
Sep-18-23 11:30AM
Sep-13-23 09:40AM
Sep-04-23 09:40AM
Jul-05-23 09:25PM
08:00AM Loading…
Jun-17-23 08:00AM
Jun-14-23 05:00PM
Jun-12-23 10:00AM
Jun-07-23 01:10AM
May-16-23 08:00AM
May-02-23 08:00AM
Apr-25-23 09:21AM
Apr-24-23 08:00AM
Apr-14-23 09:40AM
Apr-10-23 07:00PM
Apr-09-23 03:59AM
Mar-29-23 09:40AM
Mar-26-23 03:22AM
Mar-24-23 07:49AM
Mar-23-23 08:00AM
Mar-09-23 07:48AM
Mar-08-23 02:46PM
Mar-07-23 10:00AM
Mar-06-23 09:40AM
Feb-27-23 10:49PM
Feb-24-23 01:05PM
Feb-23-23 12:00PM
Feb-21-23 09:53AM
Jan-30-23 08:00AM
Jan-24-23 02:34PM
Jan-23-23 09:33AM
Jan-12-23 01:05AM
Jan-04-23 08:00PM
Jan-03-23 08:12PM
Dec-16-22 09:21AM
Dec-08-22 03:51AM
Nov-24-22 03:24AM
Nov-20-22 03:48PM
Nov-09-22 09:36AM
Nov-08-22 11:00PM
Nov-01-22 08:00AM
Oct-18-22 07:25AM
Oct-17-22 10:29AM
Oct-12-22 02:10PM
Oct-11-22 07:26PM
Sep-26-22 02:01PM
Sep-21-22 08:00AM
Sep-19-22 07:00PM
Sep-14-22 12:24PM
Sep-12-22 04:30AM
Aug-09-22 01:00AM
Aug-05-22 01:27AM
Aug-04-22 08:00AM
Jul-28-22 03:30PM
Jul-13-22 08:00AM
Jul-12-22 03:00AM
Jun-30-22 08:00AM
Jun-27-22 04:38AM
Jun-14-22 03:00AM
Jun-08-22 08:00AM
May-29-22 04:36AM
May-11-22 04:31AM
Apr-30-22 06:29AM
Apr-11-22 04:29PM
Apr-08-22 10:15AM
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.